GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn and winter is too ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

GSK Plc CEO Emma Walmsley doesn’t want the company’s employees spending any time thinking about the ongoing litigation over ...

GSK plc (GSK, GSK.L) announced the European Medicine Agency's Committee for Medicinal Products for Human Use or CHMP has recommended ...

In this piece, we will look at where GSK plc (NYSE:GSK) ranks among the top ten global ... The top three of these were a weak ...

As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza. Also Read: Medicare Drug Price Negotiation Program ...

Pharmaceutical and biotechnology company GSK said on Tuesday that the European Medicine Agency has recommended meningococcal ...

The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

ViiV Healthcare, a GSK-majority-owned HIV specialist, has committed to making at least two million doses of its long-acting ...